Please assess the completion status of the following clinical trial:

Trial Title: Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria includes:~1. Men or women ≥ 18 years~2. Subjects having IDA caused by different etiologies~3. Subjects with intolerance to oral iron therapy or a need for rapid repletion of iron stores:~4. Haemoglobin (Hb) ≤ 11 g/dL~5. Transferrin Saturation (TSAT) \< 20 %~6. S-ferritin \< 100 ng/mL~7. Willingness to participate and signing the informed consent form~Exclusion Criteria includes :~1. Anemia predominantly caused by factors other than IDA~2. Hemochromatosis or other iron storage disorders~3. Previous serious hypersensitivity reactions to any IV iron compound~4. Erythropoiesis stimulating agent (ESA) treatment~5. Prior to screening or during the trial period; has or will be treated with a red blood cell transfusion, radiotherapy, and/or chemotherapy~6. Will require a surgical procedure that necessitated general anesthesia prior to screening or during the trial period~7. Alanine aminotransferase and/or aspartate aminotransferase \> 3 times upper limit of normal~8. Required dialysis for treatment of chronic kidney disease (CKD)~9. Alcohol or drug abuse within the past 6 months~10. Pregnant or nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iron isomaltoside/ferric derisomaltose (Type: EXPERIMENTAL): Administered IV
- Iron sucrose (Type: ACTIVE_COMPARATOR): Administered IV

Based on this trial design, predict the completion outcome and termination type (if applicable).